Alterations in PTEN and PIK3CA in Colorectal Cancers in the EPIC Norfolk Study: Associations with Clinicopathological and Dietary Factors

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2011 Apr 9

PMID 21473780

Citations 39

Authors

Adam Naguib

James C Cooke

Lisa Happerfield

Lucy Kerr

Laura J Gay

Robert N Luben

Richard Y Ball

Panagiota N Mitrou

Alison McTaggart

Mark J Arends

Affiliations

Soon will be listed here.

Abstract

Background: The PTEN tumour suppressor gene and PIK3CA proto-oncogene encode proteins which contribute to regulation and propagation of signal transduction through the PI3K/AKT signalling pathway. This study investigates the prevalence of loss of PTEN expression and mutations in both PTEN and PIK3CA in colorectal cancers (CRC) and their associations with tumour clinicopathological features, lifestyle factors and dietary consumptions.

Methods: 186 adenocarcinomas and 16 adenomas from the EPIC Norfolk study were tested for PTEN and PIK3CA mutations by DNA sequencing and PTEN expression changes by immunohistochemistry. Dietary and lifestyle data were collected prospectively using seven day food diaries and lifestyle questionnaires.

Results: Mutations in exons 7 and 8 of PTEN were observed in 2.2% of CRC and PTEN loss of expression was identified in 34.9% CRC. Negative PTEN expression was associated with lower blood low-density lipoprotein concentrations (p = 0.05). PIK3CA mutations were observed in 7% of cancers and were more frequent in CRCs in females (p = 0.04). Analysis of dietary intakes demonstrated no link between PTEN expression status and any specific dietary factor. PTEN expression negative, proximal CRC were of more advanced Dukes' stage (p = 0.02) and poor differentiation (p < 0.01). Testing of the prevalence of PIK3CA mutations and loss of PTEN expression demonstrated that these two events were independent (p = 0.55).

Conclusion: These data demonstrated the frequent occurrence (34.9%) of PTEN loss of expression in colorectal cancers, for which gene mutations do not appear to be the main cause. Furthermore, dietary factors are not associated with loss of PTEN expression. PTEN expression negative CRC were not homogenous, as proximal cancers were associated with a more advanced Dukes' stage and poor differentiation, whereas distal cancers were associated with earlier Dukes' stage.

Citing Articles

Biological and Clinical Characteristics of Proximal Colon Cancer: Far from Its Anatomical Subsite.

Yang Q, Qu R, Lu S, Zhang Y, Zhang Z, Fu W Int J Med Sci. 2024; 21(10):1824-1839.

PMID: 39113889 PMC: 11302569. DOI: 10.7150/ijms.97574.

Integrative Enhancer Discovery Reveals a New Model of Enhancer Organization.

Cerda-Smith C, Hutchinson H, Liu A, Goel V, Sept C, Kim H bioRxiv. 2023; .

PMID: 37786671 PMC: 10541578. DOI: 10.1101/2023.09.20.558459.

Platelet detection as a new liquid biopsy tool for human cancers.

Chen M, Hou L, Hu L, Tan C, Wang X, Bao P Front Oncol. 2022; 12:983724.

PMID: 36185270 PMC: 9515491. DOI: 10.3389/fonc.2022.983724.

Clinicopathological Significance of PTEN Expression and Its Prognostic Effect in Colorectal Adenocarcinoma Patients.

Mirzapour Abbas Abadi Z, Samiee Rad F, Hamedi Asl D, Rahmani B, Soleimani Dodaran M, Peimani A Iran J Pathol. 2022; 17(2):150-158.

PMID: 35463728 PMC: 9013865. DOI: 10.30699/IJP.2021.531779.2653.

Comprehensive characterization of PTEN mutational profile in a series of 34,129 colorectal cancers.

Serebriiskii I, Pavlov V, Tricarico R, Andrianov G, Nicolas E, Parker M Nat Commun. 2022; 13(1):1618.

PMID: 35338148 PMC: 8956741. DOI: 10.1038/s41467-022-29227-2.

References

Samuels Y, Velculescu V . Oncogenic mutations of PIK3CA in human cancers. Cell Cycle. 2004; 3(10):1221-4. DOI: 10.4161/cc.3.10.1164. View

Abubaker J, Bavi P, Al-Harbi S, Ibrahim M, Siraj A, Al-Sanea N . Clinicopathological analysis of colorectal cancers with PIK3CA mutations in Middle Eastern population. Oncogene. 2008; 27(25):3539-45. DOI: 10.1038/sj.onc.1211013. View

Day N, McKeown N, Wong M, Welch A, Bingham S . Epidemiological assessment of diet: a comparison of a 7-day diary with a food frequency questionnaire using urinary markers of nitrogen, potassium and sodium. Int J Epidemiol. 2001; 30(2):309-17. DOI: 10.1093/ije/30.2.309. View

Campbell I, Russell S, Choong D, Montgomery K, Ciavarella M, Hooi C . Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res. 2004; 64(21):7678-81. DOI: 10.1158/0008-5472.CAN-04-2933. View

Goel A, Arnold C, Niedzwiecki D, Carethers J, Dowell J, Wasserman L . Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers. Cancer Res. 2004; 64(9):3014-21. DOI: 10.1158/0008-5472.can-2401-2. View

Chang J, Chen Y, Perng L, Wang N, Kao M, Yang T . Mutation analysis of the PTEN/MMAC1 gene in cancers of the digestive tract. Eur J Cancer. 1999; 35(4):647-51. DOI: 10.1016/s0959-8049(98)00411-0. View

Wang Z, Taylor F, Churchman M, Norbury G, Tomlinson I . Genetic pathways of colorectal carcinogenesis rarely involve the PTEN and LKB1 genes outside the inherited hamartoma syndromes. Am J Pathol. 1998; 153(2):363-6. PMC: 1852980. DOI: 10.1016/S0002-9440(10)65579-4. View

Zhou X, Loukola A, Salovaara R, Nystrom-Lahti M, Peltomaki P, de la Chapelle A . PTEN mutational spectra, expression levels, and subcellular localization in microsatellite stable and unstable colorectal cancers. Am J Pathol. 2002; 161(2):439-47. PMC: 1850747. DOI: 10.1016/S0002-9440(10)64200-9. View

Velho S, Oliveira C, Ferreira A, Ferreira A, Suriano G, Schwartz Jr S . The prevalence of PIK3CA mutations in gastric and colon cancer. Eur J Cancer. 2005; 41(11):1649-54. DOI: 10.1016/j.ejca.2005.04.022. View

10.

Naguib A, Wilson C, Adams D, Arends M . Activation of K-RAS by co-mutation of codons 19 and 20 is transforming. J Mol Signal. 2011; 6:2. PMC: 3056876. DOI: 10.1186/1750-2187-6-2. View

11.

Guanti G, Resta N, Simone C, Cariola F, Demma I, Fiorente P . Involvement of PTEN mutations in the genetic pathways of colorectal cancerogenesis. Hum Mol Genet. 1999; 9(2):283-7. DOI: 10.1093/hmg/9.2.283. View

12.

Cummings J, Bingham S . Diet and the prevention of cancer. BMJ. 1998; 317(7173):1636-40. PMC: 1114436. DOI: 10.1136/bmj.317.7173.1636. View

13.

Frattini M, Saletti P, Romagnani E, Martin V, Molinari F, Ghisletta M . PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer. 2007; 97(8):1139-45. PMC: 2360431. DOI: 10.1038/sj.bjc.6604009. View

14.

Li V, Wong C, Chan T, Chan A, Zhao W, Chu K . Mutations of PIK3CA in gastric adenocarcinoma. BMC Cancer. 2005; 5:29. PMC: 1079799. DOI: 10.1186/1471-2407-5-29. View

15.

Garcia J, Rodriguez R, Silva J, Munoz C, Dominguez G, Silva J . Intratumoral heterogeneity in microsatellite alterations in BRCA1 and PTEN regions in sporadic colorectal cancer. Ann Surg Oncol. 2003; 10(8):876-81. DOI: 10.1245/aso.2003.02.004. View

16.

Danielsen S, Lind G, Bjornslett M, Meling G, Rognum T, Heim S . Novel mutations of the suppressor gene PTEN in colorectal carcinomas stratified by microsatellite instability- and TP53 mutation- status. Hum Mutat. 2008; 29(11):E252-62. DOI: 10.1002/humu.20860. View

17.

Molinari F, Martin V, Saletti P, De Dosso S, Spitale A, Camponovo A . Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant. Br J Cancer. 2009; 100(7):1087-94. PMC: 2669991. DOI: 10.1038/sj.bjc.6604848. View

18.

Dicuonzo G, Angeletti S, Garcia-Foncillas J, Brugarolas A, Okrouzhnov Y, Santini D . Colorectal carcinomas and PTEN/MMAC1 gene mutations. Clin Cancer Res. 2001; 7(12):4049-53. View

19.

Klose R, Bird A . Genomic DNA methylation: the mark and its mediators. Trends Biochem Sci. 2006; 31(2):89-97. DOI: 10.1016/j.tibs.2005.12.008. View

20.

Benvenuti S, Frattini M, Arena S, Zanon C, Cappelletti V, Coradini D . PIK3CA cancer mutations display gender and tissue specificity patterns. Hum Mutat. 2007; 29(2):284-8. DOI: 10.1002/humu.20648. View